

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai et al.
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

[illegible]

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issues number(s), publisher, city and/or country where published.	T ²
	1	Daiichi Sankyo Company Ltd., and Eli Lilly and Company, "Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure," Press Release, August 26, 2012, Pages 1-8.	
	2	ROE et al., "Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization," N. Engl. J. Med., Pages 1-13 (August 26, 2012).	
	3	TRILOGY ACS Investigators (Duke Clinical Research Institute), "Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization - the TRILOGY ACS trial," Presentation from ESC Congress 2012, Munich, Germany (August 26, 2012)(20 pages total).	
	4	De Caterina, "TRILOGY ACS: Prasugrel versus clopidogrel for patients with Unstable Angina/NSTEMI who are medically managed without revascularization," Presentation, from ESC Congress 2012, Munich, Germany (August 26, 2012)(9 pages total).	

Examiner
Signature

Date Considered

[illegible]